A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury

BHR Pharma, LLC0 个研究点目标入组 1,180 人开始时间: 2010年6月24日最近更新: 2014年6月10日

适应症

试验速览

暂无简介。

•1.Male or female patients, age between 16 and 70 years, inclusive (or lower age limit as required by local regulations)
•2.Weight from 45 to 135 kg, inclusive.
•3.Sustained a closed head trauma no more than 8 hours before initiation of study drug infusion (exposed dura mater is acceptable in the case of depressed skull fractures)
•4.TBI diagnosed by history and clinical examination
•5.Post-resuscitation GCS score between 3 and 8, inclusive
•6.At least one reactive pupil (pinpoint pupils due to opioid pain treatment are considered reactive)
•7.Evidence of TBI confirmed by abnormalities consistent with trauma on CT scan upon admission (Diffuse injury II-IV, evacuated and non-evacuated mass lesion, Marshall’s CT Classification)
•8.Indication for ICP monitoring
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 23
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1062
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 95

•1.Life expectancy of less than 24 hours as determined by the Investigator
•2.Prolonged and/or uncorrectable hypoxia (Pa02< 60 mmHg) or hypotension (systolic blood pressure < 90 mmHg) at the time of randomization
•3.Any spinal cord injury
•4.Pregnancy
•5.Penetrating head injury
•6.Bilaterally fixed dilated pupils at the time of randomization
•7.Coma suspected to be primarily due to other causes (e.g. alcohol)
•8.Pure epidural hematoma
•9.Preexisting clinically significant disease or chronic condition that can be ascertained at the time of admission and could affect functional outcome
•10.Severe cardiac or hemodynamic instability after resuscitation prior to randomization
•11.Known treatment with another investigational drug, device, medical therapy or procedure within 30 days of injury.
•12.A history of allergic reaction to progesterone and related drugs or any of the components of the infusion
•13.Any disease, in the opinion of the Investigator, that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
•14.Subjects who, in the opinion of the Investigator, would not be able or willing to comply with the protocol through the final visit ( 6 months post-injury)

发起方